Recombinant COVID-19 Vaccine (CHO Cell) (Zifivax) Approved for Emergency Use in Colombia2022-04-20

On January 22, 2022, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. (Zhifei Longcom), the wholly-owned subsidiary of Chongqing Zhifei Bio...

Recombinant COVID-19 Vaccine (CHO Cell) (Zifivax) Approved for Heterologous Booster in Indonesia2022-04-20

On January 10, 2022, National Agency of Drug and Food Control of Indonesia (BPOM) held a press conference to announce that our Recombinant ...

Heterologous Boosting with Third Dose of Recombinant Subunit Vaccine Increases Neutralizing Antibodi2022-04-19

en.zhifeishengwu.com/skin/default/file/da91b7f0ab50b9a3f06272d6967a012e.pdf 本文转自：Emerging Microbes & lnfections...

Recombinant COVID-19 Vaccine (CHO Cell) Academic Seminar Successfully Held2022-04-18

Recently, the “Academic Seminar on the Recombinant COVID-19 Vaccine (CHO Cell)” was successfully held virtually at the Institut...

Key Data from Phase III Clinical Trials of the Recombinant COVID-19 Vaccine (CHO Cell)2022-04-15

Chongqing Zhifei Biological Products Co., Ltd (“Zhifei” or “the Company”) and its wholly-owned subsidiary Anhui Zhi...